Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Liabilities and Shareholders Equity: 2015-2024

Historic Liabilities and Shareholders Equity for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to $435.0 million.

  • Cartesian Therapeutics' Liabilities and Shareholders Equity fell 18.15% to $372.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year increase of 12.03%. This contributed to the annual value of $435.0 million for FY2024, which is 42.61% up from last year.
  • Cartesian Therapeutics' Liabilities and Shareholders Equity amounted to $435.0 million in FY2024, which was up 42.61% from $305.1 million recorded in FY2023.
  • In the past 5 years, Cartesian Therapeutics' Liabilities and Shareholders Equity registered a high of $435.0 million during FY2024, and its lowest value of $159.9 million during FY2021.
  • In the last 3 years, Cartesian Therapeutics' Liabilities and Shareholders Equity had a median value of $305.1 million in 2023 and averaged $302.0 million.
  • Per our database at Business Quant, Cartesian Therapeutics' Liabilities and Shareholders Equity dropped by 3.36% in 2021 and then spiked by 83.89% in 2023.
  • Over the past 5 years, Cartesian Therapeutics' Liabilities and Shareholders Equity (Yearly) stood at $165.4 million in 2020, then decreased by 3.36% to $159.9 million in 2021, then rose by 3.75% to $165.9 million in 2022, then skyrocketed by 83.89% to $305.1 million in 2023, then soared by 42.61% to $435.0 million in 2024.